本文選題：圍絕經(jīng)期綜合征 + 經(jīng)皮穴位電刺激　； 參考：《浙江中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的通過與電針組的隨機(jī)對(duì)照研究,觀察經(jīng)皮穴位電刺激治療肝腎陰虛型圍絕經(jīng)期綜合征的臨床療效及安全性、患者接受度評(píng)價(jià)。方法將符合納入標(biāo)準(zhǔn)的64例肝腎陰虛型圍絕經(jīng)期患者隨機(jī)分成兩組,經(jīng)皮組和電針組各32例。兩組選穴相同,均為雙側(cè)天樞、子宮、三陰交和太溪。兩組治療周期均為隔日1次,每周3次,4周為一療程。兩組在治療前后及3個(gè)月隨訪后觀察改良的Kupperman評(píng)分(KI評(píng)分)、圍絕經(jīng)期生存質(zhì)量量表(MENQOL)、血清E2、FSH的變化以及臨床整體療效的比較,并對(duì)其進(jìn)行安全性、患者接受度評(píng)價(jià)。結(jié)果(1)一般資料比較:兩組患者在年齡、病程、已絕經(jīng)患者比例上差異無統(tǒng)計(jì)學(xué)意義(P0.05),患者基本情況一致,具有可比性。(2)基線比較:治療前,兩組在KI評(píng)分、血管舒縮癥狀積分、精神神經(jīng)癥狀積分、MENQOL量表評(píng)分以及血清E2、FSH水平均無統(tǒng)計(jì)學(xué)差異(P0.05)。(3)組內(nèi)比較:兩組治療后、治療結(jié)束3個(gè)月后隨訪在KI評(píng)分、血管舒縮癥狀積分、精神神經(jīng)癥狀積分、MENQOL量表評(píng)分上與治療前相比,差異有統(tǒng)計(jì)學(xué)意義(P0.05);在血清E2水平上,兩組治療后較治療前差異有統(tǒng)計(jì)學(xué)意義(P0.05),但治療結(jié)束3個(gè)月后較治療前差異無統(tǒng)計(jì)學(xué)意義(P0.05);在血清FSH水平上,兩組治療后、治療結(jié)束3個(gè)月后較治療前差異無統(tǒng)計(jì)學(xué)意義(P0.05)。(4)組間比較:兩組治療后、治療結(jié)束3個(gè)月后隨訪在KI評(píng)分、血管舒縮癥狀積分、精神神經(jīng)癥狀積分、MENQOL量表評(píng)分以及血清E2、FSH水平上差異均無統(tǒng)計(jì)學(xué)意義(P0.05);兩組整體有效率差異無統(tǒng)計(jì)學(xué)意義(P0.05);兩組在安全性、患者接受度上差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論經(jīng)皮穴位電刺激和電針均能改善圍絕經(jīng)期綜合征患者的臨床癥狀,提高圍絕經(jīng)期綜合征患者的生存質(zhì)量;經(jīng)皮穴位電刺激改善圍絕經(jīng)期綜合征患者的臨床癥狀,提高患者生存質(zhì)量方面與電針組相較未見明顯差異,遠(yuǎn)期療效亦相當(dāng);經(jīng)皮穴位電刺激和電針均能提高圍絕經(jīng)期綜合征患者的E2水平,但遠(yuǎn)期效果不佳,經(jīng)皮穴位電刺激和電針對(duì)圍絕經(jīng)期綜合征患者的FSH水平無顯著改善;經(jīng)皮穴位電刺激的安全性、患者接受度優(yōu)于電針治療。
[Abstract]:Objective To observe the clinical efficacy and safety of percutaneous acupoint electric stimulation in the treatment of perimenopausal syndrome of yin deficiency of liver and kidney, and to evaluate the patient's acceptance. Methods 64 cases of perimenopausal patients with deficiency of liver and kidney Yin type were randomly divided into two groups, 32 cases each of the percutaneous group and the electroacupuncture group, and the two group selection phase. The two groups were both bilateral Tianshu, uterus, Sanyinjiao and Tai Xi. The two groups were 1 times a day, 3 times a week and 4 weeks as a course of treatment. The two groups were followed up before and after treatment and 3 months followed up to observe the improved Kupperman score (KI score), the perimenopausal quality of life scale (MENQOL), the changes of serum E2, FSH, and the comparison of the clinical overall effect. Safety, patient acceptance evaluation. Results (1) general data comparison: two groups of patients in age, course of disease, had no significant difference in the proportion of menopause patients (P0.05), the basic situation of the patients was consistent and comparable. (2) baseline comparison: before treatment, the two groups were scored in the KI score, the score of vasomotion symptoms, the score of mental and neurologic symptoms, and the MENQOL scale evaluation. There was no significant difference in the level of E2 and FSH (P0.05). (3) compared with the two groups, after the treatment, the follow-up was 3 months after the end of the treatment. The scores of vasomotion symptoms, the scores of mental and neurologic symptoms, and the MENQOL scale score were statistically significant (P0.05). In the serum E2 level, the two groups were compared with the treatment before treatment. The difference was statistically significant (P0.05), but the difference was not statistically significant (P0.05) after 3 months of treatment. At the level of serum FSH, there was no significant difference between the two groups after the treatment and 3 months after the end of the treatment (P0.05). (4) the two groups were treated after the treatment, and after the end of the treatment, the follow-up was in the KI score, and the symptoms of vasomotion were accumulated. The scores of mental and neurologic symptoms, MENQOL scale score, and serum E2 and FSH levels were not statistically significant (P0.05), and there was no significant difference in the overall efficiency of the two groups (P0.05); the two groups were in safety, and the difference in the acceptance of the patients was statistically significant (P0.05). Conclusion the percutaneous point electrical stimulation and electroacupuncture can improve the perimenopausal syndrome The clinical symptoms of patients with perimenopausal syndrome were improved, and the clinical symptoms of perimenopausal syndrome were improved by percutaneous acupoint electrical stimulation, and the quality of life was not significantly different from that in the electroacupuncture group, and the long-term effect was equal. The percutaneous acupoint electrical stimulation and electroacupuncture could improve perimenopausal syndrome. The E2 level, but the long-term effect is not good, the FSH level of the patients with perimenopausal syndrome is not significantly improved by the percutaneous point electrical stimulation and Electroacupuncture; the safety of the percutaneous acupoint electrical stimulation is better than the electroacupuncture treatment.

【學(xué)位授予單位】：浙江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R246.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張榮利;沈潔;沈梅紅;;針灸治療圍絕經(jīng)期綜合征臨床選穴規(guī)律的數(shù)據(jù)挖掘分析[J];針灸臨床雜志;2016年09期

2 蘇念軍;肖宗輝;呂莉娟;張?jiān)旅?黃霞;胡寶珠;熊雯雯;劉風(fēng)華;;經(jīng)皮穴位電刺激治療多囊卵巢綜合征的療效分析[J];廣西醫(yī)科大學(xué)學(xué)報(bào);2016年04期

3 徐韶怡;林江海;楊潔虹;戚茜茜;張克;柯建韓;;經(jīng)皮穴位電刺激聯(lián)合藥物治療寒濕凝滯型原發(fā)性痛經(jīng)療效觀察[J];浙江中西醫(yī)結(jié)合雜志;2016年06期

4 吳宏進(jìn);許家佗;張志楓;屠立平;張婷婷;徐蓮薇;劉巧蓮;;基于數(shù)據(jù)挖掘的圍絕經(jīng)期綜合征中醫(yī)證候分類算法分析[J];中國中醫(yī)藥信息雜志;2016年01期

5 楊華平;;經(jīng)皮穴位電刺激聯(lián)合婦科千金片治療慢性盆腔痛92例臨床研究[J];亞太傳統(tǒng)醫(yī)藥;2015年18期

6 曹徵良;王瓊;李賽群;孫佳琪;周有君;章薇;;針刺治療圍絕經(jīng)期綜合征療效系統(tǒng)評(píng)價(jià)[J];針灸臨床雜志;2015年09期

7 竇桂珍;侯艷霞;李亞珍;;經(jīng)皮穴位電刺激治療原發(fā)性痛經(jīng)(氣滯血瘀證)患者療效觀察[J];中國中醫(yī)急癥;2015年09期

8 金瑩;郭紅燕;賀豪杰;韓勁松;朱馥麗;梁華茂;孔東麗;;經(jīng)皮穴位電刺激治療女性慢性盆腔痛及痛經(jīng)的初步探討[J];中國婦產(chǎn)科臨床雜志;2015年05期

9 焦志勤;肖飛;;電針治療圍絕經(jīng)期綜合征44例臨床觀察[J];中醫(yī)藥學(xué)報(bào);2015年04期

10 馬子榮;張慶萍;;電針治療圍絕經(jīng)期綜合征臨床及機(jī)理研究[J];中醫(yī)藥臨床雜志;2015年08期

，

本文編號(hào)：1776384